股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | | 94,629,837 | | 增加 / 減少 (-) | | | | | | RMB | | | | | 本月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | | 94,629,837 | 本月底法定/註冊股本總額： RM ...

Financial Performance - Revenue increased by approximately 3.3% to RMB 772.9 million (2024: RMB 747.9 million) [3] - Gross profit rose by about 5.2% to RMB 566.2 million (2024: RMB 538.3 million) [3] - Profit for the year was RMB 24.7 million (2024: RMB 34.6 million) [3] - Earnings per share decreased to RMB 2.61 (2024: RMB 3.65) [3] - Total comprehensive income for the year amounted to RMB 22.9 million (2024: RMB 16.0 million) [4] - Other income and gains increased to RMB 8.2 million (2024: RMB 6.7 million) [4] - Selling and distribution expenses rose to RMB 460.9 million (2024: RMB 408.6 million) [4] - Administrative expenses decreased to RMB 80.9 million (2024: RMB 88.6 million) [4] - The company reported a foreign exchange loss of RMB 1.8 million (2024: RMB 18.5 million) [4] Assets and Liabilities - Total assets increased to RMB 603,463,000 (approximately USD 85.5 million) in 2025 from RMB 505,557,000 in 2024, representing a growth of 19.4% [5] - Current assets rose to RMB 392,844,000 in 2025, up from RMB 287,331,000 in 2024, marking an increase of 36.8% [5] - Non-current assets totaled RMB 210,619,000 in 2025, a slight decrease from RMB 218,226,000 in 2024, reflecting a decline of 3.0% [5] - Total liabilities increased to RMB 146,527,000 in 2025, compared to RMB 69,139,000 in 2024, indicating a significant rise of 112.5% [5] - Net assets reached RMB 456,936,000 in 2025, up from RMB 436,418,000 in 2024, showing an increase of 4.0% [6] - The company's equity attributable to owners remained stable at RMB 416,959,000 in 2025, compared to RMB 394,096,000 in 2024, reflecting a growth of 5.8% [6] - Cash and cash equivalents surged to RMB 182,323,000 in 2025 from RMB 104,530,000 in 2024, representing a substantial increase of 74.5% [5] - Trade receivables increased to RMB 53,305,000 in 2025, up from RMB 41,902,000 in 2024, which is a growth of 27.0% [5] Market and Operations - The company operates primarily in China, Australia, and New Zealand, focusing on the manufacturing and sales of nutritional dietary supplements and health foods [8] - Revenue from the Chinese market for 2025 is RMB 649,298 thousand, compared to RMB 623,538 thousand in 2024, indicating a growth of about 4.1% [13] - The group launched 27 new products in 2025, including 23 from the Good Health series and 4 from the Living Nature series [38] - The group continued to enhance its cross-border e-commerce marketing strategy, contributing to revenue growth from the Good Health brand [40] Cost and Expenses - The cost of goods sold for 2025 is RMB 203,763 thousand, slightly decreased from RMB 206,318 thousand in 2024, a reduction of about 1.3% [20] - The group reported a pre-tax profit margin for 2025, with total expenses including employee benefits amounting to RMB 110,414 thousand, up from RMB 98,354 thousand in 2024, an increase of approximately 12.3% [20] - Sales and distribution expenses increased by approximately 12.8% from about RMB 408.6 million in 2024 to about RMB 460.9 million in 2025, accounting for 59.6% of revenue [43] - Administrative expenses decreased from approximately RMB 88.6 million in 2024 to about RMB 80.9 million in the current year, representing a reduction of about 8.7% [44] Tax and Earnings - The total income tax expense for the year 2025 is CNY 2,100,000, while for 2024 it was CNY 6,320,000, reflecting a significant decrease [24] - The basic earnings per share for the year 2025 is CNY 24,665, compared to CNY 34,562 for 2024, indicating a decline in profitability [28] Inventory and Receivables - The company's total inventory for 2025 is CNY 77,636,000, down from CNY 119,085,000 in 2024, showing a reduction in stock levels [30] - Trade receivables for 2025 amount to CNY 56,431,000, an increase from CNY 45,429,000 in 2024, indicating growth in sales on credit [31] Dividends and Share Structure - The board does not recommend the payment of any final dividend for the year (2024: none) [3] - The average number of ordinary shares outstanding for both 2025 and 2024 is 946,298,370 shares, indicating no change in share structure [26] Future Outlook and Strategy - The global economy is expected to show some resilience in 2025, but growth momentum remains insufficient amid geopolitical tensions and trade protectionism [56] - The Chinese health consumption market is transitioning from "discretionary spending" to "essential demand," driven by a large population and increasing health awareness [58] - The group aims to focus on the "Good Health" brand core and continue rapid growth in the cross-border e-commerce nutrition supplement market while emphasizing quality and operational efficiency [59] - The group plans to deepen e-commerce channel promotion and enhance marketing effectiveness by optimizing input-output structures and collaborating with platforms like Xiaohongshu and Douyin [60] - Continued investment in R&D will focus on product innovation around "functional differentiation," "ingredient precision," and "convenient forms," catering to various health needs across different age groups [61] - The group will expand its overseas network while solidifying its presence in core markets like New Zealand and Australia, and actively explore emerging markets in Southeast Asia [62] - The management is confident in the long-term development prospects of the Chinese health consumption market, aiming to create greater value for shareholders through market insights and effective operational management [63] Employment and Governance - As of December 31, 2025, the group employed 524 staff, with total salary and related costs approximately RMB 129.6 million, an increase from RMB 120.8 million in the previous year [64] - The company has established an Audit Committee consisting of three independent non-executive directors, responsible for overseeing financial reporting and risk management [69] - The financial statements for the year have been audited by Ernst & Young, confirming the accuracy of the reported figures [70] - The Annual General Meeting is scheduled for June 5, 2026, with a record date for voting rights set for June 1, 2026 [72][73] - The annual results announcement will be published on the Hong Kong Stock Exchange website and the company's website [74]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NANJING SINOLIFE UNITED COMPANY LIMITED* 南 京 中 生 聯 合 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 南京中生聯合股份有限公司 董事長 桂平湖 中華人民共和國，南京，二零二六年三月十七日 於本公告日期，執行董事為桂平湖先生、張源女士及朱飛飛女士；以及獨立非執 行董事為余波先生、葉邦銀先生及程建明先生。 * 僅供識別 （股份代號：3332） 董事會會議召開日期 南京中生聯合股份有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事會」） 兹通告謹定於二零二六年三月二十七日（ 星期五 ）舉行董事會會議，以考慮及通過 本 集 團 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 的 全 年 業 績 ， 及 建 議 之 末 期 股 息 （ 如有），以及處 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NANJING SINOLIFE UNITED COMPANY LIMITED* 南 京 中 生 聯 合 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3332） 盈利警告 本 公 告 乃 由 南 京 中 生 聯 合 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法 例第571章證券及期貨條例第XIVA部之內幕消息條文（ 定義見上市規則 ）刊發。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據對本 集團截至2025年12月31日止年度未經審核綜合管理賬目作出之審閱結果，本集團 預期 錄得純 利約 人民幣 18.0 百 萬元至 人民幣 26.0 百 萬元， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | 94,629,837 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | 94,629,837 | 本月底法定/註冊股本總額： RMB 94,629,837 FF301 ...

Core Viewpoint - The stock price of Zhongsheng United (03332.HK) has shown minor fluctuations over the past week, with a range of 5.00% and a trading volume that remains low, indicating a lack of market activity [1] Group 1: Stock Performance - The stock reached a high of 0.46 HKD on February 6 and a low of 0.40 HKD on February 5 [1] - The performance of Zhongsheng United's stock was slightly better than the Hang Seng Index, which declined by 0.98% during the same period [1] Group 2: Market Activity - The total trading volume for Zhongsheng United was only 38,600 HKD, reflecting a lack of liquidity in the market [1] - Insufficient liquidity may limit the short-term volatility of the stock [1]

呈交日期: 2026年2月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | | 94,629,837 | | 增加 / 減少 (-) | | | | | | RMB | | | | | 本月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | | 94,629,837 | FF301 II. 已發行股份及 ...

致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2026年1月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 RMB | | | 0.1 RMB | | 94,629,837 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 946,298,370 RMB | | | 0.1 RMB | | 94,629,837 | 本月底法定/註冊股本總額： RMB 94,629,837 第 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 946,298,370 | | 0 | | 946,298,370 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 946,298,370 | | 0 | | 946,298,370 | 第 2 頁 共 10 頁 v 1.1.1 | 1. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 RMB | | | 0.1 RMB | | 94,629,837 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 946,298,370 RMB | | | 0.1 RMB | | 94,629,837 | 本月底法定/註冊股本總額： RMB 94,629,837 第 ...